Debiopharm, Oncodesign Services announce license agreement for use of AbYlink technology for pre-clinical services: Martigny, Switzerland Saturday, April 26, 2025, 17:00 Hrs [IST] ...

Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and ...

A claudin-1 near-infrared fluorescent antibody conjugate for in vivo primary and metastatic colorectal cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research ...

JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a ...

This valuable study provides insights into a key question in comparative neuroanatomy and development. The authors provide evidence of the role for a particular micro-RNA in regulating the development ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.